RT Journal Article
SR Electronic
T1 Serial interval, basic reproduction number and prediction of COVID-19 epidemic size in Jodhpur, India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.03.20146167
DO 10.1101/2020.07.03.20146167
A1 Saurabh, Suman
A1 Verma, Mahendra Kumar
A1 Gautam, Vaishali
A1 Goel, Akhil
A1 Gupta, Manoj Kumar
A1 Bhardwaj, Pankaj
A1 Misra, Sanjeev
YR 2020
UL http://medrxiv.org/content/early/2020/07/04/2020.07.03.20146167.abstract
AB Background Understanding the epidemiology of COVID-19 is important for design of effective control measures at local level. We aimed to estimate the serial interval and basic reproduction number for Jodhpur, India and to use it for prediction of epidemic size for next one month.Methods Contact tracing of SARS-CoV-2 infected individuals was done to obtain the serial intervals. Aggregate and instantaneous R0 values were derived and epidemic projection was done using R software v4.0.0.Results From among 79 infector-infectee pairs, the estimated median and 95 percentile values of serial interval were 5.98 days (95% CI 5.39 – 6.65) and 13.17 days (95% CI 11.27 – 15.57), respectively. The overall R0 value in the first 30 days of outbreak was 1.64 (95% CI 1.12 – 2.25) which subsequently decreased to 1.07 (95% CI 1.06 – 1.09). The instantaneous R0 value over 14 days window ranged from a peak of 3.71 (95% CI 1.85 -2.08) to 0.88 (95% CI 0.81 – 0.96) as on 24 June 2020. The projected COVID-19 case-load over next one month was 1881 individuals. Reduction of R0 from 1.17 to 1.085 could result in 23% reduction in projected epidemic size over the next one month.Conclusion Aggressive testing, contact-tracing and isolation of infected individuals in Jodhpur district resulted in reduction of R0. Further strengthening of control measures could lead to substantial reduction of COVID-19 epidemic size. A data-driven strategy was found useful in surge capacity planning and guiding the public health strategy at local level.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors declare that no funding was received from any source for the study and preparation of this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Ethics Committee of AIIMS, Jodhpur, India.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData on which the study is based is included in the manuscript and in the supplementary files.